A5067073596- CAR-T cell therapy research
- Synthesis and Biological Evaluation
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Cytomegalovirus and herpesvirus research
- Silicon Carbide Semiconductor Technologies
- CNS Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- Complement system in diseases
- Epigenetics and DNA Methylation
Inserm
2019-2025
Sorbonne Université
2019-2025
Centre d'Immunologie et des Maladies Infectieuses
2019-2025
Centre National de la Recherche Scientifique
2021-2025
Université Paris Cité
2021-2024
Assistance Publique – Hôpitaux de Paris
2024
Institut de recherche Saint-Louis
2023
Abstract Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies cells using CAR are needed. SLAMF7 (also known as CS1) CD38 on tumor plasma represent potential alternative targets in myeloma, but their expression activated T other hematopoietic raises concerns about the efficacy safety of such treatments. Here, we used CRISPR/Cas9 deletion gene developed...
EBV-positive and EBV-negative posttransplant lymphoproliferative disorders (PTLDs) arise in different immunovirological contexts might have distinct pathophysiologies. To examine this hypothesis, we conducted a multicentric prospective study with 56 39 PTLD patients of the K-VIROGREF cohort, recruited at diagnosis before treatment (2013-2019), compared them to PTLD-free Transplant Controls (TC, n = 21). We measured absolute lymphocyte counts (n 108), analyzed NK- T cell phenotypes 49 94),...
The fate of hematopoietic stem and progenitor cells (HSPCs) is regulated by their interaction with stromal in the bone marrow. However, cellular mechanisms regulating HSPC these potential impact on polarity are still poorly understood. Here we evaluated cell–cell contacts osteoblasts or endothelial HSPC. We found that an can form a discrete contact site leads to extensive polarization its cytoskeleton architecture. Notably, centrosome was located proximity site. capacity HSPCs polarize...
Non-Hodgkin lymphomas (NHL) commonly occur in immunodeficient patients, both those infected by human immunodeficiency virus (HIV) and who have been transplanted, are often driven Epstein-Barr (EBV) with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated immunogenomics 68 lymphoproliferative disorders from 51 (34 post-transplant, 17 HIV+) immunocompetent patients. Overall, 72% were large B-cell lymphoma 25% primary...
Kidney transplant recipients (KTRs) abnormally replicate the Epstein Barr Virus (EBV). To better understand how long-term immunosuppression impacts immune control of this EBV re-emergence, we systematically compared 10 clinically stable KTRs to 30 healthy controls (HCs). The EBV-specific T cell responses were determined in both groups by multiparameter flow cytometry with intra cellular cytokine staining (KTRs n = 10; HCs 15) and ELISpot-IFNγ assays 7; 7). T/B/NK counts 30) NK/T...
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 3</p>
<div>Abstract<p>Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies cells using CAR are needed. SLAMF7 (also known as CS1) CD38 on tumor plasma represent potential alternative targets in myeloma, but their expression activated T other hematopoietic raises concerns about the efficacy safety of such treatments. Here, we used CRISPR/Cas9 deletion...
<p>Supplementary Figure 5</p>
<div>Abstract<p>Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies cells using CAR are needed. SLAMF7 (also known as CS1) CD38 on tumor plasma represent potential alternative targets in myeloma, but their expression activated T other hematopoietic raises concerns about the efficacy safety of such treatments. Here, we used CRISPR/Cas9 deletion...
<p>Supplementary Figure 1</p>
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM) targeting B-cell maturation (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies MM cells by CAR-T are needed. SLAMF7 (CS1) CD38 on tumour plasma represent potential alternative targets in MM, but their expression activated T other hematopoietic raises concerns about the efficacy safety of such treatments. Here, we used CRISPR/Cas9 deletion gene developed DCAR, a...
The immunopathological pulmonary mechanisms leading to Coronavirus Disease (COVID-19)-related death in adults remain poorly understood. Bronchoalveolar lavage (BAL) and peripheral blood sampling were performed 74 steroid non-steroid-treated intensive care unit (ICU) patients (23–75 years; 44 survivors). Peripheral effector SARS-CoV-2-specific T cells detected 34/58 cases, mainly directed against the S1 portion of spike protein. BAL lymphocytosis consisted cells, while mean CD4/CD8 ratio was...